Grape Seeds: Ripe for Cancer Chemoprevention

Santosh K. Katiyar1,2 and Mohammad Athar1

Abstract
A wide variety of phytochemicals, mostly flavonoids or polyphenolics, have been shown to possess anticarcinogenic activities. Among these are the grape seed proanthocyanidins (GSPs), which are the active ingredients of grape seed extract (GSE). Substantial in vitro and preclinical in vivo studies have shown the chemopreventive efficacy of GSPs against various forms of cancers in different tumor models. In this issue of the journal, Derry and colleagues show that administration of GSE in the diet reduces azoxymethane-induced colon carcinoma in an A/J mouse model. The results of this innovative and comprehensive study indicate that inhibition of azoxymethane-induced colon cancer by dietary GSE is mediated through the induction of apoptosis that is associated with alterations in microRNA (miRNA) and cytokine expression profiles as well as β-catenin signaling. Notably, the demonstration that miRNA expression is affected by dietary GSE suggests a novel underlying mechanism for the chemopreventive action of GSE in colon cancer and, potentially, other cancers. Cancer Prev Res; 6(7); 617–21. ©2013 AACR.

Introduction
Natural products including dietary components, herbs, and spices have been used for the prevention of many diseases, including cancer, for centuries. Today, there is renewed interest in natural phytochemicals as promising options for the development of more effective chemopreventive or chemotherapeutic strategies for various types of cancer. Full realization of this potential, however, requires an improved knowledge of the effects of these natural products. Two major lines of enquiry are being pursued: first, identification of the components of the plant, or the dietary agent derived from the plants that are responsible for the anticancer effects and second, elucidation of the mechanisms of action of these components and identification of the specific mechanisms that play a role in reducing the risk of cancer.

Grape seed extract (GSE), which is readily prepared from grape (Vitis vinifera) seeds, is a by-product of the grape juice and wine industries. Indeed, it is available in the United States and sold as an over-the-counter health dietary supplement in the form of capsule or tablet formulations containing 100 to 500 mg. It has been shown that GSE is a mixture of several polyphenolic components. Proanthocyanidins, which include dimers, trimers, tetramers, and oligomers/polymers of monomeric catechins and/or (+)-epicatechin units, are considered to be a major fraction of GSE (1, 2). The proanthocyanidins are naturally occurring compounds that are found in numerous different plants. They are distributed variously among the fruits, vegetables, nut, seeds, flowers, and bark. The proanthocyanidins represent the major type of polyphenols in red wine; however, the seeds of grapes are a particularly rich source. The current interest in the biology of GSE originated with reports describing epidemiologic data related to the population of France that showed that despite consumption of a diet high in saturated fat, this population manifests a low incidence of coronary heart disease. To describe these observations, the term ‘French Paradox’ was coined. It was suggested that moderate red wine consumption may be associated with a lower incidence of coronary heart disease in this population. Since red wine is a rich source of GSPs, this prompted interest in testing the cellular effects of GSE and GSPs, including assessment of their chemopreventive or chemotherapeutic efficacy.

Proanthocyanidins are synonymous with condensed tannins and also known as oligomeric proanthocyanidins, pycnogenols or leucocyanidins, and oligomers or polymers of flavan-3-ols. The monomeric units in these oligomers are linked primarily through C4—C8 bond, but the C4—C6 linkages are also present (Fig. 1). These linkages are called B-type linkages (1, 2). The presence of high amounts of oligomeric procyanidins and polymeric compounds (such as tannins) as a result of condensation of flavan-3-ols is responsible for various aesthetic and taste-related qualities of red wine. These agents may also contribute significantly to the pharmacologic properties of grape seeds. The most common types of ingredients and linkages are shown in Fig. 1. The most abundant types of proanthocyanidins in plants are the procyanidins, which consist exclusively of epicatechin units. Various factors can affect the content of the phenolic constituents in grapes. The content is known to be affected by agroecologic factors such as the cultivar; the year
of production, which is of interest for the most part because of the climatic condition during that year; the geographic location, which affects soil chemistry, the use of fertilizers, etc.; and the degree of fruit maturation. The GSPs have been subjected to toxicity testing, including analysis of the acute and subchronic toxicity in rats and genotoxicity testing. The results of this testing indicate that these compounds are of low toxicity and have no genotoxic potential (2, 3).

During the last decade, multiple preclinical studies have been carried out using in vitro approaches and in vivo analyses in animal models that show the protective effects of GSE and its active constituents grape seed proanthocy-

Figure 1. Chemical structures of the monomers (flavan-3-ols), dimers (B1, B2), and trimers (C1, C2) present in GSE.
involved reactivation of silenced tumor suppressor genes in skin cancer cells as a consequence of epigenetic reprogramming (20).

Both in vitro studies and in vivo studies in animals have generated additional insights into the mechanisms underlying the anticancer effects of GSPs/GSE. Recently, we provided compelling evidence that GSPs have the ability to reverse the epithelial–mesenchymal transition (EMT) in cancer cells by affecting the expression of various proteins that orchestrate the migration of invasive cancer cells during metastasis. Using in vitro cell culture models, we have shown that treatment of melanoma (21), non–small cell lung cancer (NSCLC) cells (22), pancreatic cancer cells (23), and head and neck squamous cell carcinoma (HNSCC) cells (9) with GSPs significantly inhibited the migration ability or invasive potential of these cells. GSPs inhibit melanoma cell invasiveness by reduction of COX-2 expression, PGE2 production, and reversal of EMT in these cells (21). This characteristic of GSPs is important because melanoma is the leading cause of death from skin disease due, in large part, to its propensity to metastasize (24). Moreover, its incidence in children is increasing rapidly (25). HNSCC is responsible for approximately 20,000 deaths and affects more than 40,000 people in the United States annually (26). EGFR is overexpressed in 90% of HNSCCs and is considered as a critical target in its treatment. Using a cell invasion assay, we found that treatment of HNSCC cells with GSPs resulted in inhibition of cell invasion, which was associated with the reduced levels of EGFR and its downstream target NF-κB (9). Overexpression of EGFR and high NFκB activity play key roles in the EMT, which is of critical importance in the processes underlying metastasis, and it was found that treatment of cancer cells with GSPs reversed the EMT process and promoted the mesenchymal–epithelial transition instead. Bioactive components of GSPs also inhibit the growth of HNSCC cells in vitro as well as in vivo in an athymic nude mouse model by targeting multiple signaling molecules/pathways (10). These targets include: (i) inhibition of cell proliferation, (ii) induction of apoptosis, (iii) regulation of dysregulated cell cycle and its checkpoints, and (iv) reactivation of tumor suppressor proteins. Similar effects of GSPs also were observed when pancreatic cancer cells were treated with GSPs (23). Pancreatic cancer is an aggressive malignancy that is frequently diagnosed at an advanced stage with poor prognosis (27). Using in vitro studies and an in vivo athymic nude mouse model, Prasad and colleagues (28) have shown that GSPs inhibit pancreatic cancer cell growth through induction of apoptosis and by targeting the PI3K/Akt pathway. The PI3K/Akt pathway is a fundamental signaling pathway that mediates several cellular processes, including cell proliferation, growth, cell survival, and motility (29). Lung cancer remains the leading cause of cancer related deaths in the United States and worldwide. NSCLC represents approximately 80% of all types of lung cancer. Although a combination of chemotherapy and radiation therapy can improve survival of the patients, most patients die of disease progression, often resulting from acquired or intrinsic resistance to chemotherapeutic drugs (30). Thus, it is of interest that the results of a recent study revealed that treatment of human NSCLC cells with GSPs induces apoptosis by loss of mitochondrial membrane potential in both in vitro and in vivo models (31). This preclinical study also indicated that dietary GSPs inhibit the growth of human NSCLC xenografts by targeting insulin-like growth factor binding protein-3 and inhibition of tumor angiogenesis (11). The previously mentioned GSPs-induced inhibitory effects on PGE2 and PGE2 receptors also have been associated with the inhibition of human NSCLC cells growth (12). As the metastasis of lung cancer cells is considered as a major cause of death, the effect of GSPs on lung cancer cell migration/invasion was also investigated. Punathil and Katiyar have reported that treatment of human NSCLC cells with GSPs resulted in inhibition of migration of these cells, and the inhibition of cancer cell
migration by GSPs was associated with the sequential inhibition of nitric oxide, guanylate cyclase, and MAPK pathways (22). Similarly, administration of dietary GSE inhibited the growth and progression of prostate cancer in the TRAMP mouse model with these effects being associated with its inhibition of prostate cancer cell proliferation and angiogenesis (7, 8). These studies indicate that GSPs may be highly efficacious if used as an adjuvant during the therapeutic intervention of highly aggressive metastatic cancers in humans. Collectively, the information derived from these studies provide important leads in terms of potential chemopreventive strategies and the identification of specific molecular markers that could be used to evaluate the chemopreventive efficacy of the GSPs against various form of cancers.

With respect to chemoprevention of colon cancer by GSE, in vitro studies using Fischer 344 rats have shown that dietary GSE significantly inhibits azoxymethane (AOM)-induced formation of colonic aberrant crypt foci (ACF) in terms of crypt multiplicity (32). This study also showed that feeding of GSE inhibited AOM-induced cell proliferation and enhanced apoptosis in colon including ACF, which was associated with the reduction in the expression of COX-2, iNOS, cyclin D1, and survivin. The reduction in colonic ACF by GSE also was correlated with a reduction in AOM-induced increase in β-catenin and NF-kB as compared with the group of rats that were not given GSE in diet. In another study, the same group showed that treatment of colon carcinoma HT29 cells with GSE inhibited cell growth and induced apoptotic cell death, which was associated with the induction of Cip1/p21 protein and phosphorylation of ERK1/2 (33). In this issue, Agarwal and colleagues (34) report the results of an extension of their previous studies and show a mechanism-based chemopreventive action of GSE in models of colorectal carcinogenesis. Employing the A/J mouse model, these authors showed that dietary GSE prevents AOM-induced colon carcinogenesis and that this was associated with the antiproliferative and proapoptotic activities of GSE. This study provides elegant mechanistic evidence to support the concept that GSE targets cytokine/inflammation signaling pathways by modulating the expression of microRNAs (miRNA). Notably, the authors employed a highly relevant model, i.e., AOM-induced colon tumorigenesis in A/J mice that resembles inflammation-associated human colorectal carcinogenesis in terms of the progression of disease from aberrant crypt foci to polyps, adenoma, and carcinomas (34). Treatment of dietary GSE resulted in a significant reduction in both colon and small intestine tumor multiplicity and size with a concomitant reduction in proliferation-related biomarkers and increase in apoptosis-related proteins. A unique aspect of this study is the application of anatomical gadolinium-enhanced T1-weighted magnetic resonance imaging noninvasive technology to track the progression of the disease. This showed the slow progression of the disease in real time with respect to GSE feeding. A second important aspect of this study is the comprehensive evaluation of potential targets. The authors verified that NF-kB, β-catenin, and MAPKs signaling pathways are targeted by GSE as well as a significant reduction in the expression of cytokines/chemokines and other inflammation-predicting biomarkers. Notably, they also extended the analyses to include analysis of miRNAs. The importance of miRNA in cancer biology is becoming increasingly apparent with numerous reports now showing a correlation between their expression and disease prognosis in a variety of cancers. It is therefore of considerable importance that these authors found that GSE regulated the expression profile of a broad spectrum of miRNAs (miR-19a, miR-20a, miR-let7a, miR-205, miR-135b, miR-196a, miR-21, miR-148a, and miR-103), as well as the miRNA processing machinery. Further in-depth investigations, which were not a part of this current study, are required to understand the mechanism by which phytochemicals like GSE may affect miRNA homeostasis. Undoubtedly, this study provides a direction for further translational investigations with a view to develop chemopreventive agents that can specifically modulate the expression of miRNA and abrogate colon cancer development. In addition, the angiogenesis regulatory pathway, another important target pathway of these bioactive GSE, needs to be further investigated.

The chemopreventive studies employing various dietary polyphenols conducted in various cell culture and murine models of multiple cancer types are of great interest and suggest that these complex mixtures that are present as secondary metabolites in plants are pharmacologically active and important. It should be noted, however, that the results of clinical trials of these phytochemicals are often not very encouraging (35). Major questions have been raised about their bioavailability and degradation profiles in human tissues and must be resolved. This issue is complicated by the difficulties inherent in obtaining pharmacokinetic values for complex mixtures. Safety issues, particularly the possibility of heavy metal contamination of the agents and the estrogenic activities associated with many of the phytochemicals, are other impediments in the development of these agents. From the in vitro and in vivo animal data and molecular target identification studies, it seems that the use of GSE/GSPs alone or in an adjuvant setting with other chemotherapeutic agents or drugs in patients with cancer may be highly promising. Thus, the current challenge is to accelerate laboratory studies that will advance the knowledge of the mechanisms of action of GSE in a manner that facilitates clinical applications.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Grant Support**

The work reported from the author’s laboratory is supported by the Veterans Administration Merit Review Award (to S.K. Katiyar) and NIH (CA166883; to S.K. Katiyar).

Received May 23, 2013; accepted May 23, 2013; published online July 2, 2013.
References

1. Priece Jr, Rigaud J, Cheynier V, Moutounet M. Oligomeric and poly-
2. Nandakumar V, Singh T, Katiyar SK. Multi-targeted prevention and
therapy of cancer by proanthocyanidins. Cancer Lett 2008;375:
162–7.
3. Yamakoshi J, Salto M, Kataoka S, Kikuchi M. Safety evaluation of
proanthocyanidins-rich extract from grape seeds. Food Chemical
4. Zhao J, Wang J, Chen Y, Agarwal R. Anti-tumor-promoting activity of
a polyphenolic fraction isolated from grape seeds in the mouse skin two-
stage initiation-promotion protocol and identification of procyanidin
B5-3-galactoside as the most effective antioxidant constituent. Carcino-
genesis 1999;20:1737–45.
5. Mittal A, Elments CA, Katiyar SK. Dietary feeding of proanthocyanidins
from grape seeds prevents photocarcinogenesis in SKH-1 hairless mice:
Relation to decreased fat and lipid peroxidation. Carcino-
6. Mantena SK, Baliga MS, Katiyar SK. Grape seed proanthocyanidins
induce apoptosis and inhibit metastasis of highly metastatic breast
7. Singh RP, Tyagi AK, Dhanalakshmi S, Agarwal R, Agarwal C. Grape
seed extract inhibits advanced human prostate tumor growth and
angiogenesis and upregulates insulin-like growth factor binding pro-
8. Raina K, Singh RP, Agarwal R, Agarwal C. Oral grape seed extract
inhibits the growth of human non-small cell lung cancer xenografts by
 targeting EGFR and the epithelial-to-mesenchymal transition. PLoS ONE
2009;4:e5532.
9. Sun Q, Prasad R, Rosenthal E, Katiyar SK. Grape seed procyanidins
inhibit the invasive potential of pancreatic cancer cells by promoting mesenchymal-
to-epithelial transition and targeting NF-κB. Cancer Lett 2010;304:
10. American Cancer Society. Melanoma skin cancer. Available at : http://
11. Strouse JJ, Fears TR, Tucker MA, Wayne AS. Pediatric melanoma: risk
12. Arbes SJ Jr, Olshan AF, Caplan DJ, Schoenbach VJ, Slade GD,
Symons MJ. Factors contributing to the poorer survival of black
Americans diagnosed with oral cancer (United States). Cancer Cause
14. Prasad R, Vaid M, Katiyar SK. Grape seed proanthocyanidins inhibit
pancreatic cancer cell growth in vitro and in vivo through induction of
apoptosis and by targeting the PI3K/Akt pathway. PLoS ONE 2012;7:
e43064.
15. Luo J, Manning BD, Cantley LC. Targeting the PI3K–Akt pathway in
16. Fer蒂n-Gómez O, Buccheri G. Second-line chemotherapy for recurrent non-
 small cell lung cancer: do new agents make a difference? Lung Cancer
17. Singh T, Sharma SD, Katiyar SK. Grape seed proanthocyanidins induce
apoptosis by loss of mitochondrial membrane potential of human non-small cell lung
18. Velmurugan B, Singh RP, Agarwal R, Agarwal C. Dietary feeding of
grape seed extract prevents azoxymethane-induced colon aberrant
19. Velmurugan B, Singh RP, Agarwal R, Agarwal C. Dietary feeding of
grape seed extract upregulates p21 (Cip1) through redox-mediated activa-
20. Velmurugan B, Singh RP, Agarwal R, Agarwal C. Dietary feeding of
grape seed extract prevents azoxymethane-induced colonic aberrant
crypt foci formation in A/J mice: interlinking miRNA with cytokine signaling
21. Velmurugan B, Singh RP, Agarwal R, Agarwal C. Dietary feeding of
grape seed extract upregulates p21 (Cip1) through redox-mediated activa-
22. Velmurugan B, Singh RP, Agarwal R, Agarwal C. Dietary feeding of
grape seed extract prevents azoxymethane-induced colon aberrant
crypt foci formation in A/J mice: interlinking miRNA with cytokine signaling
23. Velmurugan B, Singh RP, Agarwal R, Agarwal C. Dietary feeding of
grape seed extract prevents azoxymethane-induced colon aberrant
crypt foci formation in A/J mice: interlinking miRNA with cytokine signaling
24. Velmurugan B, Singh RP, Agarwal R, Agarwal C. Dietary feeding of
grape seed extract prevents azoxymethane-induced colon aberrant
crypt foci formation in A/J mice: interlinking miRNA with cytokine signaling
25. Velmurugan B, Singh RP, Agarwal R, Agarwal C. Dietary feeding of
grape seed extract prevents azoxymethane-induced colon aberrant
crypt foci formation in A/J mice: interlinking miRNA with cytokine signaling
26. Velmurugan B, Singh RP, Agarwal R, Agarwal C. Dietary feeding of
grape seed extract prevents azoxymethane-induced colon aberrant
crypt foci formation in A/J mice: interlinking miRNA with cytokine signaling
Grape Seeds: Ripe for Cancer Chemoprevention
Santosh K. Katiyar and Mohammad Athar


Updated version
Access the most recent version of this article at:
doi:10.1158/1940-6207.CAPR-13-0193

Supplementary Material
Access the most recent supplemental material at:
http://cancerpreventionresearch.aacrjournals.org/content/suppl/2013/07/03/1940-6207.CAPR-13-0193.DC1

Cited articles
This article cites 34 articles, 14 of which you can access for free at:
http://cancerpreventionresearch.aacrjournals.org/content/6/7/617.full.html#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
/content/6/7/617.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.